Butylscopolammonium vs rhinopront
Mechanistic comparison of Butylscopolammonium Bromide Antimuscarinic quaternary ammonium derivative of scopolamine used to treat cramps in gastrointestinal and rhinopront syrup [Supplementary Concept] contains 300 mg phenylpropanolamine and 24 mg carbinoxamine per 100 g based on molecular target overlap from BindingDB and ChEMBL binding affinity data.
2
Shared Targets
33%
Jaccard Similarity
27%
IDF-Weighted Similarity
Jaccard measures raw target overlap. IDF-weighted downweights promiscuous hub targets (e.g. CYP enzymes) that bind many compounds non-specifically.
Evidence Comparison
Butylscopolammonium Bromide Antimuscarinic quaternary ammonium derivative of scopolamine used to treat cramps in gastrointestinal
—
Evidence Score
33
PubMed Studies
View full profile →
rhinopront syrup [Supplementary Concept] contains 300 mg phenylpropanolamine and 24 mg carbinoxamine per 100 g
—
Evidence Score
—
PubMed Studies
View full profile →
Target Overlap
Butylscopolammonium and rhinopront share 2 molecular targets based on binding affinity data from BindingDB (Kd/IC50 ≤ 10 µM) and ChEMBL. A Jaccard index of 0.333 means 33% of the combined target set is bound by both compounds. The IDF-weighted score of 0.265 accounts for non-specific binding to metabolic enzymes.
Note: High target overlap does not imply identical mechanism or therapeutic equivalence. Binding affinity, tissue distribution, bioavailability, and downstream signaling differ significantly between compounds even when they bind the same protein.